Edition:
United States

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

21.57USD
15 Dec 2017
Change (% chg)

$-0.09 (-0.42%)
Prev Close
$21.66
Open
$21.70
Day's High
$22.05
Day's Low
$21.54
Volume
1,049,751
Avg. Vol
152,577
52-wk High
$24.50
52-wk Low
$10.44

Latest Key Developments (Source: Significant Developments)

Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic
Tuesday, 28 Nov 2017 08:30am EST 

Nov 28 (Reuters) - Cytomx Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC.CYTOMX THERAPEUTICS INC - ‍IND ACCEPTANCE RESULTS IN A $10 MILLION MILESTONE PAYMENT TO CYTOMX​.CYTOMX THERAPEUTICS INC - ‍BRISTOL-MYERS SQUIBB HAS RECEIVED ACCEPTANCE OF IND FROM U.S. FDA FOR A CTLA-4-DIRECTED PROBODY THERAPEUTIC​.  Full Article

CytomX reports Q3 loss per share $‍0.28​
Tuesday, 7 Nov 2017 04:58pm EST 

Nov 7 (Reuters) - CytomX Therapeutics Inc :CytomX announces third quarter 2017 financial results and operational progress.Q3 revenue $24.1 million versus $3.5 million.Q3 revenue view $17.5 million -- Thomson Reuters I/B/E/S.CytomX Therapeutics Inc qtrly loss per share $‍0.28​.  Full Article

Amgen, CytomX therapeutics announce strategic collaboration in Immuno-Oncology
Tuesday, 3 Oct 2017 06:21pm EDT 

Oct 3 (Reuters) - Amgen Inc ::Amgen and CytomX Therapeutics announce strategic collaboration in immuno-oncology.Co will lead later development and commercialization with global late-stage development costs shared between co, CytomX.Under agreement, Co, CytomX to co-develop probody T-cell engaging bispecific against EGFRXCD3 with CytomX leading early development.Under agreement, co will make upfront payment of $40 million and purchase $20 million of cytomx common stock.CytomX will be eligible to receive up to $455 million in development, regulatory and commercial milestones for EGFR program.CytomX to be able to opt into profit share in U.S., receive tiered, double-digit royalties on sales outside of U.S. for EGFR program.Under agreement, Co will also receive exclusive worldwide rights to develop and commercialize up to three additional, undisclosed targets.Should Co pursue all of undisclosed targets, CytomX to be eligible to receive up to $950 million in additional upfront, milestone payments.If Co pursues undisclosed targets, CytomX to also be eligible to get high single-digit to mid-double digit royalties on resulting products.CytomX will also receive rights from co to undisclosed preclinical T-cell engaging bispecific program.is eligible to receive milestones, royalty payments on resulting products from undisclosed preclinical t-cell engaging bispecific program.  Full Article

Cytomx Therapeutics Q2 loss per share $ 0.69​
Monday, 7 Aug 2017 04:05pm EDT 

Aug 7 (Reuters) - Cytomx Therapeutics Inc :Cytomx announces second quarter 2017 financial results and mid-year update webcast conference call.Q2 revenue $8.8 million versus $3.1 million.Q2 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Cytomx Therapeutics Inc - ‍as of June 30, 2017, Cytomx had cash, cash equivalents and short-term investments of $335.9 million​.Cytomx Therapeutics- ‍based upon current operating plan, company expects its existing capital resources will be sufficient to fund operations into 2020​.Cytomx Therapeutics Inc - ‍remain on track to disclose data from initial probody clinical trials in 2018​.Cytomx Therapeutics Inc qtrly ‍net loss per share, basic and diluted $ 0.69​.  Full Article

Canaan IX LP dissolves passive stake in Cytomx Therapeutics as of June 7 - SEC filing
Friday, 7 Jul 2017 09:07am EDT 

July 7 (Reuters) - Cytomx Therapeutics Inc :Canaan IX LP dissolves passive stake in Cytomx Therapeutics Inc as of June 7 - SEC filing.Canaan IX LP says had previously reported a passive stake of 8.9 percent as of December 31, 2016.  Full Article

BVF Partners LP reports 5.5 pct passive stake in CytomX Therapeutics as of June 19 - SEC Filing
Friday, 30 Jun 2017 06:18am EDT 

June 30 (Reuters) - Cytomx Therapeutics Inc :BVF Partners LP reports 5.5 percent passive stake in CytomX Therapeutics Inc as of June 19 - SEC Filing.  Full Article

CytomX achieves development milestone in collaboration with AbbVie
Thursday, 29 Jun 2017 08:00am EDT 

June 29 (Reuters) - CytomX Therapeutics Inc ::CytomX achieves development milestone in strategic oncology collaboration with AbbVie for CD71-targeting probody drug conjugate.CytomX Therapeutics Inc - will receive a $15 million milestone payment from AbbVie as part of 2016 strategic oncology collaboration between companies.  Full Article

Cytomx announces management team changes
Monday, 15 May 2017 04:01pm EDT 

May 15 (Reuters) - Cytomx Therapeutics Inc :Cytomx announces management team changes.Bob Goeltz, chief financial officer, has decided to leave company to pursue new opportunities.Cytomx Therapeutics Inc - Cytomx is appointing Debanjan Ray as chief financial officer and head of corporate development, effective immediately.  Full Article

CytomX Therapeutics qtrly loss per share $ 0.23
Friday, 5 May 2017 08:00am EDT 

May 5 (Reuters) - CytomX Therapeutics Inc :CytomX announces first quarter 2017 financial results.Q1 revenue $11.7 million versus $2.2 million.Q1 revenue view $4 million -- Thomson Reuters I/B/E/S.Qtrly loss per share $ 0.23.Q1 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.CytomX Therapeutics Inc - company expects its existing capital resources will be sufficient to fund operations at least through 2019.  Full Article

Bristol-Myers Squibb, Cytomx Therapeutics extend worldwide collaboration
Monday, 20 Mar 2017 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb and Cytomx Therapeutics extend worldwide collaboration to discover Probody Therapeutics for the treatment of cancer and other diseases . Bristol-Myers Squibb Co - Cytomx to receive $200 million upfront payment . Bristol-Myers Squibb - Cytomx will also be eligible to receive up to $448 million in future development, regulatory,sales milestone payments for each collaboration target . Bristol-Myers Squibb Co - collaboration includes up to eight additional targets in oncology and other therapeutic areas .Bristol-Myers Squibb Co - Cytomx will grant Bristol-Myers Squibb exclusive worldwide rights to develop and commercialize Probody Therapeutics.  Full Article

BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic

* CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC